Analysts expect over 2019 rising revenue Biogen

Tomorrow the American Biogen will report its past quarters results. For this year Biogen's revenue will be around 13,95 billion USD. This is according to the average of the analysts' estimates. This is slightly more than 2018's revenue of 13,45 billion USD.

Historical revenues and results Biogen plus estimates 2019

The analysts expect for 2019 a net profit of 5,73 billion USD. Most of the analysts anticipate on a profit per share of 29,66 USD. The PE-ratio therefore is 7,8.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is a low 0,5 percent.

Recent target prices around 231 USD

The most recent recommendations for the biotech company are from Piper Jaffray, Citigroup and Credit Suisse.

Based on the current number of outstanding shares Biogen's market capitalization is 48,91 billion USD. The Biogen stock was the past 12 months quite volatile. Since last July the stock is 36 percent lower. This year the stock price moved between 216 and 389 dollar.

On Monday the stock closed at 231,27 USD.

Price data Biogen 2007-2019

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.